Emcure Pharmaceuticals Ltd (NSE: EMCURE, BSE: 544210) is a Pune, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹42,344 Cr, it ranks #230 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 63 in Pharmaceuticals. At ₹2,348.00 (as of 16 Nov 2026), the share price is 3.4% below its 52-week high of ₹2,429.90 and 78.9% above its 52-week low of ₹1,312.30. The share price is up 73.3% over one year and up 17.5% over three months.
| Current Price | ₹2,348.00 |
|---|---|
| Market Cap | ₹42,344 Cr |
| NSE Symbol | EMCURE |
| BSE Code | 544210 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 47.9 |
| Return on Equity | 19.57% |
| Return on Assets | 9.62% |
| 52-Week Range | ₹1,312.30 – ₹2,429.90 |
| 1-Year Price Change | +73.3% |
| 3-Month Price Change | +17.5% |
| Beta (1Y) | -0.19 |
| Dividend Yield | 0.15% |
| Headquarters | Pune, Maharashtra |
| Website | www.emcure.com |
| Revenue | ₹2,820 Cr |
|---|---|
| Net Profit | ₹325 Cr |
| Net Margin | 11.5% |
| EPS (Basic) | ₹17.16 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Emcure Pharmaceuticals Ltd reported revenue of ₹2,820 Cr in Q2 FY27, up 24.3% from ₹2,270 Cr in Q2 FY26 and up 9.3% from ₹2,580 Cr in Q1 FY27. It posted a net profit of ₹325 Cr for the quarter, against a net profit of ₹251 Cr in Q2 FY26 (up 29.3%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹2,101 Cr (Q1 FY26) to ₹2,820 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹2,820 Cr | ₹325 Cr | 11.5% |
| Q1 FY27 | ₹2,580 Cr | ₹292 Cr | 11.3% |
| Q4 FY26 | ₹2,470 Cr | ₹244 Cr | 9.9% |
| Q3 FY26 | ₹2,363 Cr | ₹231 Cr | 9.8% |
| Q2 FY26 | ₹2,270 Cr | ₹251 Cr | 11.1% |
| Q1 FY26 | ₹2,101 Cr | ₹215 Cr | 10.2% |
| Q4 FY25 | ₹2,116 Cr | ₹197 Cr | 9.3% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 77.82% of Emcure Pharmaceuticals Ltd's shares as of Sept 2026, against 77.88% in Sept 2025 (−0.06 percentage points). Delivery averaged 53.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.
1. Pharmaceuticals-This segment engages in the development, manufacture, and marketing of various pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Astrazeneca Pharma India Ltd. | ₹16,078 Cr | 85.9 | 22.82% | ₹729 Cr | -34.3% |
Listed by market capitalisation. Ratios are shown for context only.
Emcure Pharmaceuticals Ltd is trading at ₹2,348.00, with a market capitalisation of ₹42,344 Cr.
Emcure Pharmaceuticals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Emcure Pharmaceuticals Ltd has a P/E of 47.9 and a return on equity of 19.57%.
Emcure Pharmaceuticals Ltd is listed on the NSE under the symbol EMCURE and on the BSE under the scrip code 544210.
Emcure Pharmaceuticals Ltd's share price is up 73.3% over one year and up 17.5% over three months. Its 52-week range is ₹1,312.30 to ₹2,429.90.
In Q2 FY27, Emcure Pharmaceuticals Ltd reported revenue of ₹2,820 Cr and net profit of ₹325 Cr, with basic EPS of ₹17.16 (consolidated, parsed from the company's exchange filing).
Emcure Pharmaceuticals Ltd reported revenue of ₹2,820 Cr in Q2 FY27, up 24.3% from ₹2,270 Cr in Q2 FY26 and up 9.3% from ₹2,580 Cr in Q1 FY27.
Promoters held 77.82% of Emcure Pharmaceuticals Ltd's shares as of Sept 2026, against 77.88% in Sept 2025 (−0.06 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.